| Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy. | |
| | |
MedLine Citation:
|
PMID: 20939798 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Diabetic retinopathy is a common and devastating microvascular complication in diabetes and is a leading cause of acquired blindness among the people of occupational age. Recent large landmark clinical studies have shown that intensive control of blood glucose or blood pressure (BP) reduces the risk for diabetic retinopathy. However, the strict control of blood glucose or BP is often difficult to maintain. Further, current therapeutic options for the treatment of sight-threatening proliferative diabetic retinopathy (PDR) such as photocoagulation and vitrectomy are limited by considerable side effects and far from satisfactory. Therefore, to develop novel therapeutic strategies that specifically target PDR is actually desired for most patients with diabetes. Although various biochemical and hemodynamic pathways are implicated in the diabetic retinopathy, recent clinical study has substantiated the concept of 'metabolic memory', and suggested the active involvement of advanced glycation end products (AGEs) and oxidative stress in this sight-threatening disorder. We, along with others, have recently found that pigment epithelium-derived factor (PEDF), a glycoprotein with complex neuroprotective, anti-angiogenic, anti-oxidative, and anti-inflammatory properties, could potentially be exploited as a therapeutic option for the treatment of diabetic retinopathy. Therefore, this article summarizes the role of AGEs and oxidative stress in diabetic retinopathy and discusses a potential utility of the blockade of this system by PEDF in this devastating disorder. |
| | |
Authors:
|
Sho-Ichi Yamagishi; Takanori Matsui |
Related Documents
:
|
11815348 - The hermann-hering grid illusion demonstrates disruption of lateral inhibition processi... 16937378 - Validation of a novel immunocytochemical assay for topoisomerase ii-alpha and minichrom... 9467128 - Prevalence and correlations of early microvascular complications in young type i diabet... 18976928 - Inhibition of aldose reductase from cataracted eye lenses by finger millet (eleusine co... 7039948 - The role of glucagon in diabetes. 17785698 - Igf-i treatment of insulin resistance. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current pharmaceutical biotechnology Volume: 12 ISSN: 1873-4316 ISO Abbreviation: Curr Pharm Biotechnol Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-02-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100960530 Medline TA: Curr Pharm Biotechnol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 362-8 Citation Subset: IM |
Affiliation:
|
Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anti-angiogenesis drugs in diabetic retinopathy.
Next Document: Fluocinolone acetonide implantable device for diabetic retinopathy.